




Catalog # 10-3986

FR-027

3-(3,5-bis(Trifluoromethyl)phenyl)-1-(1-methyl-4-nitro-1H-imidazol-5-yl)-1H-1,2,4-triazole

CAS# 3054389-11-3

Lot # FBA11102



FR-027 is a novel inhibitor of Exportin 1 (XPO1/CRM1). Unlike other XPO1 inhibitors, it reacts with Cys528 through nucleophilic aromatic substitution instead of Michael addition, does not induce degradation of XPO1, and reversibly inhibits XPO1-mediated nuclear export. FR-027 displays EC50s <1 μ M against multiple solid and hematological tumor cell lines. It is active in vivo, increasing overall survival rates in MOLT-4 T-ALL xenograft, syngeneic ID8-fLuc ovarian cancer, and xenograft brain tumor mouse models without inducing thrombocytopenia, lymphopenia, or neutropenia.

- 1) Van Hauwenhuyse *et al.* (2026), *Preclinical characterization of a reversible XPO1 inhibitor for cancer therapy*; Nat. Commun. **17** 8940

PHYSICAL DATA

Molecular Weight: 406.25

Molecular Formula: C₁₄H₁₈F₆N₆O₂

Purity: >98% by HPLC

NMR: Conforms

Solubility: DMSO (60 mg/mL)

Physical Description: White solid

Storage and Stability: Store as supplied desiccated at -20°C for up to 2 years from the date of purchase.
Solutions in DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.